Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018
Statin-Associated Autoimmune Myopathy
NEJM 374:664-669, Mammen, A.L., 2016
Inflammatory Muscle Diseases
NEJM 372:1734-1747, Dalakas, M.C., 2015
Infections of the Nervous System, (Bacterial, Fungal, Spirochetal, Parasitic) and Sarcoidosis, Sarcoidosis
Adams & Victors Principles of Neurology, Chp 32, pg 721, Ropper, A.H.,et al, 2014
The Spectrum of Statin Myopathy
Curr Opin Rheumatol 25:747-752, Mohassel, P. & Mammen, A.L., 2013
Inflammatory Myopathies with Anti-Ku Antibodies
Medicine 91:95-102, Rigolet,A.,et al, 2012
Mycophenolate Mofetil May Be Effective in CNS Sarcoidosis But Not in Sarcoid Myopathy
Neurol 76:1168-1172, Androdias,G.,et al, 2011
Clinicopathologic Conference, Susacs Syndrome (retinocochleocerebral vasculopathy)
NEJM 365:549-559, Case 24-2011, 2011
Evaluation and Treatment of Inflammatory Myopathies
JNNP 80:1060-1068, Amato,A. &Barohn,R.J., 2009
Juvenile Dermatomyositis and Other Idiopathic Inflammatory Myopathies of Childhood
Lancet 371:2201-2212, Feldman,B.M.,et al., 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Whipples Disease
NEJM 356:55-66, Fenollar,F.,et al, 2007
Mycophenolate Mofetil in Dermatomyositis: Is It Safe?
Neurol 66:1245-1247, Rowin,J.,et al, 2006
Polymyositis and Dermatomyositis
Lancet 362:971-982, Dalakas,M.C.&Hohlfeld,R., 2003
The Neurologic Complications of Scleromyxedema
Medicine 80:313-319, Berger,J.R.,et al, 2001
Churg-Strauss Syndrome, Clinical Study and Long-Term Follow-Up of 96 Patients
Medicine 78:26-37, Guillevin,L.,et al, 1999
Treatment of Inflammatory Myopathies
Muscle & Nerve 20:651-664997., Mastaglia,F.L.,et al, 1997
Linomide Reduces the Rate of Active Lesions in Relapsing-Remitting Multiple Sclerosis
Neurol 47:895-900, Anderson,O.,et al, 1996
Drug Therapy of Idiopathic Inflammatory Myopathies:Response to Prednisone Azathioprine, & Methotrexate
Am J Med 94:379-387, Joffe,M.M.,et al, 1993
The Treatment of Inclusion Body Myositis:A Retrospective Review & Random, Prospective Trial of Immunosupp Therapy
Medicine 72:225-235, Leff,R.L.,et al, 1993
Treatment of Inclusion-Body Myositis with High-Dose Intravenous Immunoglobulin
Neurol 43:876-879, Soueidan,S.A.&Dalakas,M.C., 1993
Generalized Myositis in Behcet Disease:TReatment with Cyclosporine
Ann Int Med 116:651-653, Lingenfelser,T.,et al, 1992
The Idiopathic Inflammatory Myopathies and Their Treatment
JNNP 54:285-287, Walton,J., 1991
Polymyositis, Dermatomyositis, and Inclusion-Body Myositis
NEJM 325:1487-1498, Dalakas,M.C., 1991
Cyclosporin in the Management of Polymyositis and Dermatomyositis
JNNP 54:1007-1008, Lueck,C.J.,et al, 1991
Current Concepts in the Idiopathic Inflammatory Myopathies:Polymyositis, Dermatomyositis, and Related Disorders
Ann Int Med 111:143-157, Plotz,P.H.,et al, 1989
Inclusion Body Myositis, Observations in 40 Patients
Brain 112:727-747, Lotz,B.P.,et al, 1989
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Clin Characteristics, Course, & Diag Criteria
Arch Neurol 46:878-884, Barohn,R.J.,et al, 1989
Takayasu's Arteritis & Its Therapy
Ann Int Med 103:121-126, Shelhamer,J.H.,et al, 1985
Plasmapheresis in Idiopathic Inflammatory Myopathy Experience With 35 Patients
Arch Neurol 38:544-552, Dau,P.C., 1981
Immunosppressive Agents in Corticosteroid-Refractory Childhood Dermatomyositis
Neurol 30:286-291, Niakan,E.,et al, 1980
Long-term Administration of Corticosteroids in Myasthenia Gravis
Neurol 26:729, Mann,J.D.,et al, 1976
Polymyositis & Dermatomyositis
NEJM 292:344, 1975, 292:403975., Bohan,A.,et al, 1975
Clinical Presentation, Investigation Findings, and Outcomes of IgG4-Related Pachymeningitis,A Systematic Review
JAMA Neurol 82:193-199, Terrim,S.,et al, 2025
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Immunosuppressive Therapy Reversing Obstructive Hydrocephalus in CLIPPERS
Neurol 102:e209396, Yang,Y.,et al, 2024
Herpes Simplex Virus Encephalitis in Patients with Autoimmune Conditions or Exposure to Immunomodulatory Medications
Neurol 102:e209297, Tang,A.,et al, 2024
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
Confused About Confusion
NEJM 386:80-87, Spanjaart, A.M.,et al, 2022
Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis
Neurol 98:e2368-e2376, Molimard, A.,et al, 2022
A New Option is Approved for Patients with Myasthenia Gravis
JAMA 327:417, Voelker, R., 2022
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Pregnancy in Patients with AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder
Neurol 96:e2006-e2015, Collongues, N.,et al, 2021
Clinicopathologic Conference, Cerebral Amyloid Angiopatny-Related Inflammation
NEJM 385:358-368, Case 22-2021, 2021
A 47-Year-Old With Headache, Vertigo, and Double Vision
Neurol 97:e535-e539, Frey, J.,et al, 2021